IFNW1 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "IFNW1" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

5doi.org

2^nd place

1ensembl.org

1,626^th place

1,007^th place

1harvard.edu

18^th place

17^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Olopade OI, Bohlander SK, Pomykala H, Maltepe E, Van Melle E, Le Beau MM, Diaz MO (Dec 1992). "Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia". Genomics. 14 (2): 437–43. doi:10.1016/S0888-7543(05)80238-1. PMID 1385305.
Schultz U, Kaspers B, Staeheli P (May 2004). "The interferon system of non-mammalian vertebrates". Developmental and Comparative Immunology. 28 (5): 499–508. doi:10.1016/j.dci.2003.09.009. PMID 15062646.
Li SF, Zhao FR, Shao JJ, Xie YL, Chang HY, Zhang YG (2017). "Interferon-omega: Current status in clinical applications". Int Immunopharmacol. 52: 253–260. doi:10.1016/j.intimp.2017.08.028. PMC 7106160. PMID 28957693.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. (2011). "Structural linkage between ligand discrimination and receptor activation by type I interferons". Cell. 146 (4): 621–32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, et al. (2022). "Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity". Nat Commun. 13 (1): 7254. Bibcode:2022NatCo..13.7254S. doi:10.1038/s41467-022-34895-1. PMC 9700809. PMID 36434007.{{cite journal}}: CS1 maint: multiple names: authors list (link)

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000177047 – Ensembl, May 2017

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, et al. (2022). "Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity". Nat Commun. 13 (1): 7254. Bibcode:2022NatCo..13.7254S. doi:10.1038/s41467-022-34895-1. PMC 9700809. PMID 36434007.{{cite journal}}: CS1 maint: multiple names: authors list (link)

nih.gov (Global: 4^th place; English: 4^th place)

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: IFNW1 interferon, omega 1".
Li SF, Zhao FR, Shao JJ, Xie YL, Chang HY, Zhang YG (2017). "Interferon-omega: Current status in clinical applications". Int Immunopharmacol. 52: 253–260. doi:10.1016/j.intimp.2017.08.028. PMC 7106160. PMID 28957693.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. (2011). "Structural linkage between ligand discrimination and receptor activation by type I interferons". Cell. 146 (4): 621–32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, et al. (2022). "Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity". Nat Commun. 13 (1): 7254. Bibcode:2022NatCo..13.7254S. doi:10.1038/s41467-022-34895-1. PMC 9700809. PMID 36434007.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Horton HM, Hernandez P, Parker SE, Barnhart KM (1999). "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice". Cancer Res. 59 (16): 4064–8. PMID 10463608.{{cite journal}}: CS1 maint: multiple names: authors list (link)

pubmed.ncbi.nlm.nih.gov

Olopade OI, Bohlander SK, Pomykala H, Maltepe E, Van Melle E, Le Beau MM, Diaz MO (Dec 1992). "Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia". Genomics. 14 (2): 437–43. doi:10.1016/S0888-7543(05)80238-1. PMID 1385305.
Schultz U, Kaspers B, Staeheli P (May 2004). "The interferon system of non-mammalian vertebrates". Developmental and Comparative Immunology. 28 (5): 499–508. doi:10.1016/j.dci.2003.09.009. PMID 15062646.
Li SF, Zhao FR, Shao JJ, Xie YL, Chang HY, Zhang YG (2017). "Interferon-omega: Current status in clinical applications". Int Immunopharmacol. 52: 253–260. doi:10.1016/j.intimp.2017.08.028. PMC 7106160. PMID 28957693.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. (2011). "Structural linkage between ligand discrimination and receptor activation by type I interferons". Cell. 146 (4): 621–32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, et al. (2022). "Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity". Nat Commun. 13 (1): 7254. Bibcode:2022NatCo..13.7254S. doi:10.1038/s41467-022-34895-1. PMC 9700809. PMID 36434007.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Horton HM, Hernandez P, Parker SE, Barnhart KM (1999). "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice". Cancer Res. 59 (16): 4064–8. PMID 10463608.{{cite journal}}: CS1 maint: multiple names: authors list (link)

IFNW1 (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 1,626th place; English: 1,007th place)